Skip to content
2000
image of Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study

Abstract

Introduction

Maternal chronic immune and inflammatory conditions may predispose newborns to atypical developmental trajectories, identifying pregnancy as a key period for the etiopathogenesis of neurodevelopmental disorders. The possible long-term impact of maternal multiple sclerosis (MS) on the offspring’s cognitive and behavioral development and its pharmacological treatment during pregnancy is mostly unknown. This study aims to delineate the cognitive and behavioral profile of offsprings exposed to maternal MS, untreated or treated with Natalizumab throughout pregnancy, in comparison to a control group.

Methods

We retrospectively enrolled 39 children (23 males; 16 females; mean age 45.82 ± 35.46 months) exposed to maternal MS, untreated or treated with Natalizumab throughout pregnancy, and 36 children (24 males; 12 females, mean age 38.03 ± 21.52 months) of healthy mothers. All offspring underwent a standardized evaluation of their intellectual or developmental quotient, adaptive functioning, and behavioral issues, including symptoms of autism.

Results

The clinical profile of the included offspring was characterized by an adequate cognitive profile and a good level of adaptive skills (MS offspring: Griffiths III mean total DQ (N = 30) 114.57; WISC-IV mean Full IQs (N= 9) 115.44; mean ABAS GAC 97.28/Control offspring: Griffiths III mean total DQ (N = 31) 105.42; WISC-IV mean Full IQs (N= 4) 119.25 ± 11.32; mean ABAS GAC 97.82 ± 21.4). Furthermore, no significant behavioural problems or autism symptoms emerged in the entire group, regardless of MS treatment.

Conclusion

Offspring's developmental and behavioral phenotypes do not appear to be influenced by maternal treatment with Natalizumab until late pregnancy, nor by maternal variables directly related to MS (age at the time of MS diagnosis, disease duration, and severity).

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X370866250416103923
2025-07-04
2025-07-20

  • From This Site

    /content/journals/cn/10.2174/011570159X370866250416103923
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 5ª ed., text rev. American Psychiatric Association 2022 10.1176/appi.books.9780890425787
    [Google Scholar]
  2. Heyer D.B. Meredith R.M. Environmental toxicology: Sensitive periods of development and neurodevelopmental disorders. Neurotoxicology 2017 58 23 41 10.1016/j.neuro.2016.10.017 27825840
    [Google Scholar]
  3. Emberti Gialloreti L. Mazzone L. Benvenuto A. Fasano A. Garcia Alcon A. Kraneveld A. Moavero R. Raz R. Riccio M.P. Siracusano M. Zachor D.A. Marini M. Curatolo P. Risk and protective environmental factors associated with autism spectrum disorder: Evidence-based principles and recommendations. J. Clin. Med. 2019 8 2 217 10.3390/jcm8020217 30744008
    [Google Scholar]
  4. Loke Y.J. Hannan A.J. Craig J.M. The role of epigenetic change in autism spectrum disorders. Front. Neurol. 2015 6 107 10.3389/fneur.2015.00107 26074864
    [Google Scholar]
  5. Styles M. Alsharshani D. Samara M. Alsharshani M. Khattab A. Qoronfleh M. W. Al-Dewik N. I. Risk factors, diagnosis, prognosis and treatment of autism. Front Biosci (Landmark Ed) 2020 25 9 1682 1717 10.2741/4873
    [Google Scholar]
  6. Posner J. Polanczyk G.V. Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet 2020 395 10222 450 462 10.1016/S0140‑6736(19)33004‑1 31982036
    [Google Scholar]
  7. Leblond C.S. Le T.L. Malesys S. Cliquet F. Tabet A.C. Delorme R. Rolland T. Bourgeron T. Operative list of genes associated with autism and neurodevelopmental disorders based on database review. Mol. Cell. Neurosci. 2021 113 103623 10.1016/j.mcn.2021.103623 33932580
    [Google Scholar]
  8. Doi M. Usui N. Shimada S. Prenatal Environment and Neurodevelopmental Disorders. Front Endocrinol (Lausanne). 2022 13 860110 10.3389/fendo.2022.860110
    [Google Scholar]
  9. Fang S.Y. Wang S. Huang N. Yeh H.H. Chen C.Y. Prenatal infection and autism spectrum disorders in childhood: A population-based case-control study in Taiwan. Paediatr. Perinat. Epidemiol. 2015 29 4 307 316 10.1111/ppe.12194 25989831
    [Google Scholar]
  10. Lee B.K. Magnusson C. Gardner R.M. Blomström Å. Newschaffer C.J. Burstyn I. Karlsson H. Dalman C. Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. Brain Behav. Immun. 2015 44 100 105 10.1016/j.bbi.2014.09.001 25218900
    [Google Scholar]
  11. Knuesel I. Chicha L. Britschgi M. Schobel S.A. Bodmer M. Hellings J.A. Toovey S. Prinssen E.P. Maternal immune activation and abnormal brain development across CNS disorders. Nat. Rev. Neurol. 2014 10 11 643 660 10.1038/nrneurol.2014.187 25311587
    [Google Scholar]
  12. Estes M.L. McAllister A.K. Maternal immune activation: Implications for neuropsychiatric disorders. Science 2016 353 6301 772 777 10.1126/science.aag3194 27540164
    [Google Scholar]
  13. Balestrieri E. Cipriani C. Matteucci C. Benvenuto A. Coniglio A. Argaw-Denboba A. Toschi N. Bucci I. Miele M.T. Grelli S. Curatolo P. Sinibaldi-Vallebona P. Children with autism spectrum disorder and their mothers share abnormal expression of selected endogenous retroviruses families and cytokines. Front. Immunol. 2019 10 2244 10.3389/fimmu.2019.02244 31616420
    [Google Scholar]
  14. Balestrieri E. Matteucci C. Cipriani C. Grelli S. Ricceri L. Calamandrei G. Sinibaldi Vallebona P. Endogenous retroviruses activity as a molecular signature of neurodevelopmental disorders. Int. J. Mol. Sci. 2019 20 23 6050 10.3390/ijms20236050 31801288
    [Google Scholar]
  15. Rosenberg M.D. Baby brains reflect maternal inflammation. Nat. Neurosci. 2018 21 5 651 653 10.1038/s41593‑018‑0134‑0 29632358
    [Google Scholar]
  16. Siracusano M. Riccioni A. Gialloreti L. Carloni E. Baratta A. Ferrara M. Arturi L. Lisi G. Adulti I. Rossi R. Lucaselli A. Rossi A. Niolu C. Mazzone L. Maternal perinatal depression and risk of neurodevelopmental disorders in offspring: preliminary results from the SOS MOOD project. Children (Basel) 2021 8 12 1150 10.3390/children8121150 34943347
    [Google Scholar]
  17. Gaillard R. Santos S. Duijts L. Felix J.F. Childhood health consequences of maternal obesity during pregnancy: A narrative review. Ann. Nutr. Metab. 2016 69 3-4 171 180 10.1159/000453077 27855382
    [Google Scholar]
  18. Segovia S.A. Vickers M.H. Reynolds C.M. The impact of maternal obesity on inflammatory processes and consequences for later offspring health outcomes. J. Dev. Orig. Health Dis. 2017 8 5 529 540 10.1017/S2040174417000204 28343461
    [Google Scholar]
  19. Rakers F. Rupprecht S. Dreiling M. Bergmeier C. Witte O. W. Schwab M. Transfer of maternal psychosocial stress to the fetus. Neurosci Biobehav Rev 2017 22 S0149-7634(16)30719-9 10.1016/j.neubiorev.2017.02.019 28237726
    [Google Scholar]
  20. Graham A.M. Rasmussen J.M. Rudolph M.D. Heim C.M. Gilmore J.H. Styner M. Potkin S.G. Entringer S. Wadhwa P.D. Fair D.A. Buss C. Maternal systemic interleukin-6 during pregnancy is associated with newborn amygdala phenotypes and subsequent behavior at 2 years of age. Biol. Psychiatry 2018 83 2 109 119 10.1016/j.biopsych.2017.05.027 28754515
    [Google Scholar]
  21. Spann M.N. Monk C. Scheinost D. Peterson B.S. Maternal immune activation during the third trimester is associated with neonatal functional connectivity of the salience network and fetal to toddler behavior. J. Neurosci. 2018 38 11 2877 2886 10.1523/JNEUROSCI.2272‑17.2018 29487127
    [Google Scholar]
  22. Li Y.M. Ou J.J. Liu L. Zhang D. Zhao J.P. Tang S.Y. Association between maternal obesity and autism spectrum disorder in offspring: A meta-analysis. J. Autism Dev. Disord. 2016 46 1 95 102 10.1007/s10803‑015‑2549‑8 26254893
    [Google Scholar]
  23. Instanes J.T. Halmøy A. Engeland A. Haavik J. Furu K. Klungsøyr K. Attention-deficit/hyperactivity disorder in offspring of mothers with inflammatory and immune system diseases. Biol. Psychiatry 2017 81 5 452 459 10.1016/j.biopsych.2015.11.024 26809250
    [Google Scholar]
  24. Krakowiak P. Walker C.K. Bremer A.A. Baker A.S. Ozonoff S. Hansen R.L. Hertz-Picciotto I. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics 2012 129 5 e1121 e1128 10.1542/peds.2011‑2583 22492772
    [Google Scholar]
  25. Thompson A.J. Banwell B.L. Barkhof F. Carroll W.M. Coetzee T. Comi G. Correale J. Fazekas F. Filippi M. Freedman M.S. Fujihara K. Galetta S.L. Hartung H.P. Kappos L. Lublin F.D. Marrie R.A. Miller A.E. Miller D.H. Montalban X. Mowry E.M. Sorensen P.S. Tintoré M. Traboulsee A.L. Trojano M. Uitdehaag B.M.J. Vukusic S. Waubant E. Weinshenker B.G. Reingold S.C. Cohen J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 17 2 162 173 10.1016/S1474‑4422(17)30470‑2 29275977
    [Google Scholar]
  26. Wang Y. Wang J. Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun. Rev. 2023 22 11 103449 10.1016/j.autrev.2023.103449 37741528
    [Google Scholar]
  27. McGinley M.P. Goldschmidt C.H. Rae-Grant A.D. Diagnosis and treatment of multiple sclerosis. JAMA 2021 325 8 765 779 10.1001/jama.2020.26858 33620411
    [Google Scholar]
  28. Mendibe Bilbao M. Boyero Durán S. Bárcena Llona J. Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women’s health issues. Neurología (Engl. Ed.) 2019 34 4 259 269 10.1016/j.nrleng.2016.06.014 27546613
    [Google Scholar]
  29. Bove R. Sutton P. Nicholas J. Women’s health and pregnancy in multiple sclerosis. Neurol. Clin. 2024 42 1 275 293 10.1016/j.ncl.2023.07.004 37980119
    [Google Scholar]
  30. Krysko K.M. Dobson R. Alroughani R. Amato M.P. Bove R. Ciplea A.I. Fragoso Y. Houtchens M. Jokubaitis V.G. Magyari M. Abdelnasser A. Padma V. Thiel S. Tintore M. Vukusic S. Hellwig K. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023 22 4 350 366 10.1016/S1474‑4422(22)00426‑4 36931808
    [Google Scholar]
  31. Hellwig K. Verdun di Cantogno E. Sabidó M. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2021 14 17562864211051012 10.1177/17562864211051012 34876925
    [Google Scholar]
  32. Vukusic S. Carra-Dalliere C. Ciron J. Maillart E. Michel L. Leray E. Guennoc A. M. Bourre B. Laplaud D. Androdias G. Bensa C. Bigaut K. Biotti D. Branger P. Casez O. Cohen M. Daval E. Deschamps R. Donze C. Dubessy A. L. Lebrun-Frenay C. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler 2023 29 1 11 36 10.1177/13524585221129472 36317497
    [Google Scholar]
  33. Modrego P.J. Urrea M.A. de Cerio L.D. The effects of pregnancy on relapse rates, disability and peripartum outcomes in women with multiple sclerosis: a systematic review and meta-analysis. J. Comp. Eff. Res. 2021 10 3 175 186 10.2217/cer‑2020‑0211 33565886
    [Google Scholar]
  34. Siracusano M. Carloni E. Riccioni A. Ferrara M. Scoppola C. Arturi L. Niolu C. Marfia G.A. Mazzone L. Maternal multiple sclerosis and offspring’s cognitive and behavioral development: what do we know until now? Children 2022 9 11 1716 10.3390/children9111716 36360444
    [Google Scholar]
  35. Andersen J.B. Moberg J.Y. Niclasen J. Laursen B. Magyari M. Mental health among children of mothers with multiple sclerosis: A Danish cohort and register‐based study. Brain Behav. 2018 8 10 e01098 10.1002/brb3.1098 30242988
    [Google Scholar]
  36. Diareme S. Tsiantis J. Kolaitis G. Ferentinos S. Tsalamanios E. Paliokosta E. Anasontzi S. Lympinaki E. Anagnostopoulos D.C. Voumvourakis C. Romer G. Emotional and behavioural difficulties in children of parents with multiple sclerosis. Eur. Child Adolesc. Psychiatry 2006 15 6 309 318 10.1007/s00787‑006‑0534‑7 16614788
    [Google Scholar]
  37. Razaz N. Tremlett H. Boyce W. T. Guhn M. Joseph K. S. Marrie R. A. Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. Mult Scler 2015 21 9 1172 83 10.1177/1352458514559298
    [Google Scholar]
  38. Fink K. Gorczyca A. Alping P. Englund S. Farmand S. Langer-Gould A.M. Piehl F. McKay K. Frisell T. Razaz N. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult. Scler. 2023 29 6 731 740 10.1177/13524585231161492 37073483
    [Google Scholar]
  39. Landi D. Bovis F. Grimaldi A. Annovazzi P.O. Bertolotto A. Bianchi A. Borriello G. Brescia Morra V. Bucello S. Buscarinu M.C. Caleri F. Capobianco M. Capra R. Cellerino M. Centonze D. Cerqua R. Chisari C.G. Clerico M. Cocco E. Cola G. Cordioli C. Curti E. d’Ambrosio A. D’Amico E. De Luca G. Di Filippo M. Di Lemme S. Fantozzi R. Ferraro D. Ferraro E. Gallo A. Gasperini C. Granella F. Inglese M. Lanzillo R. Lorefice L. Lus G. Malucchi S. Margoni M. Mataluni G. Mirabella M. Moiola L. Nicoletti C.G. Nociti V. Patti F. Pinardi F. Portaccio E. Pozzilli C. Ragonese P. Rasia S. Salemi G. Signoriello E. Vitetta F. Totaro R. Sormani M.P. Amato M.P. Marfia G.A. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2022 jnnp-2022-329657 Advance online publication 10.1136/jnnp‑2022‑329657 36180219
    [Google Scholar]
  40. Schubert C. Steinberg L. Peper J. Ramien C. Hellwig K. Köpke S. Solari A. Giordano A. Gold S.M. Friede T. Heesen C. Rahn A.C. Postpartum relapse risk in multiple sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2023 94 9 718 725 10.1136/jnnp‑2022‑330533 36807056
    [Google Scholar]
  41. Dobson R. Dassan P. Roberts M. Giovannoni G. Nelson-Piercy C. Brex P.A. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract. Neurol. 2019 19 2 106 114 10.1136/practneurol‑2018‑002060 30612100
    [Google Scholar]
  42. Varytė G. Zakarevičienė J. Ramašauskaitė D. Laužikienė D. Arlauskienė A. Pregnancy and multiple sclerosis: an update on the disease modifying treatment strategy and a review of pregnancy’s impact on disease activity. Medicina 2020 56 2 49 10.3390/medicina56020049 31973138
    [Google Scholar]
  43. Thiel S. Litvin N. Haben S. Gold R. Hellwig K. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. J. Neurol. Neurosurg. Psychiatry 2024 95 6 561 570 10.1136/jnnp‑2023‑332804 38124108
    [Google Scholar]
  44. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis. Neurology 1983 33 11 1444 1452 10.1212/WNL.33.11.1444 6685237
    [Google Scholar]
  45. Green E. Griffiths Scales of Child Development. 3rd ed Oxford Hogrefe 2016
    [Google Scholar]
  46. Wechsler D. Wechsler Intelligence Scale for Children. 4th ed San Antonio Psychological Corporation 2003 25923224
    [Google Scholar]
  47. Oakland T. Kreutzer J.S. DeLuca J. Caplan B. Adaptive Behavior Assessment System. Encyclopedia of clinical neuropsychology. 2nd ed New York Springer 2011 10.1007/978‑0‑387‑79948‑3_1506
    [Google Scholar]
  48. Achenbach T.M. Rescorla L.A. Manual for the ASEBA preschool forms & profiles. Burlington University of Vermont 2000
    [Google Scholar]
  49. Lord C. Rutter M. Autism Diagnostic Observation Schedule. 2nd ed Torrance Western Psychological Services 2012
    [Google Scholar]
  50. Esler A.N. Bal V.H. Guthrie W. Wetherby A. Weismer S.E. Lord C. The autism diagnostic observation schedule, toddler module: Standardized severity scores. J. Autism Dev. Disord. 2015 45 9 2704 2720 10.1007/s10803‑015‑2432‑7 25832801
    [Google Scholar]
  51. Carta A. Zarbo I.R. Scoppola C. Pisuttu G. Conti M. Melis M.C. Martino F.D. Serra A. Biancu M.A. Guerini F.R. Bazzardi R. Sotgiu S. Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Mult. Scler. J. Exp. Transl. Clin. 2021 7 2 20552173211017301 10.1177/20552173211017301 34104473
    [Google Scholar]
  52. Razaz N. Joseph K. S. Boyce W. T. Guhn M. Forer B. Carruthers R. Marrie R. A. Tremlett H. Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. Mult Scler 2016 22 11 1452 1462 10.1177/1352458515621624 26683589
    [Google Scholar]
  53. Mahlanza T. D. Manieri M. C. Klawiter E. C. Solomon A. J. Lathi E. Ionete C. Berriosmorales I. Severson C. Stankiewicz J. Cabot A. Elkort M. Chitnis T. Bove R. Katz J. Houtchens M. Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. Mult Scler 2021 27 1 79 89 10.1177/1352458520904545 32065561
    [Google Scholar]
  54. Andersen M.L. Jølving L.R. Stenager E. Knudsen T. Nørgård B.M. Maternal multiple sclerosis and health outcomes among the children: A systematic review. Clin. Epidemiol. 2023 15 375 389 10.2147/CLEP.S392273 36969978
    [Google Scholar]
  55. Fink K. Gorczyca A. Alping P. Englund S. Farmand S. Langer-Gould A. M. Piehl F. McKay K. Frisell T. Razaz N. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study 2023 29 6 731 740 10.1177/13524585231161492
    [Google Scholar]
  56. Marozio L. Cavalla P. Sottemano S. Vercellino M. Federici F. Cosma S. Peila C. Cresi F. Coscia A. Capobianco M. Bosa C. Schillaci V. Bellisario V. Migliaretti G. Benedetto C. Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control stud. Mult. Scler. Relat. Disord. 2022 65 104087 10.1016/j.msard.2022.104087 35933740
    [Google Scholar]
  57. Lord C. Charman T. Havdahl A. Carbone P. Anagnostou E. Boyd B. Carr T. de Vries P.J. Dissanayake C. Divan G. Freitag C.M. Gotelli M.M. Kasari C. Knapp M. Mundy P. Plank A. Scahill L. Servili C. Shattuck P. Simonoff E. Singer A.T. Slonims V. Wang P.P. Ysrraelit M.C. Jellett R. Pickles A. Cusack J. Howlin P. Szatmari P. Holbrook A. Toolan C. McCauley J.B. The Lancet Commission on the future of care and clinical research in autism. Lancet 2022 399 10321 271 334 10.1016/S0140‑6736(21)01541‑5 34883054
    [Google Scholar]
  58. Misirliyan S.S. Boehning A.P. Shah M. Development Milestones. StatPearls. StatPearls Publishing 2023
    [Google Scholar]
  59. Lejarraga H. Kelmansky D.M. Passcucci M.C. Masautis A. Insua I. Lejarraga C. Nunes F. Assessment of child psychomotor development in population groups as a positive health indicator. Arch. Argent. Pediatr. 2016 114 1 23 29 10.5546/aap.2016.eng.23 26914071
    [Google Scholar]
  60. Kover S.T. Edmunds S.R. Ellis Weismer S. Brief Report: Ages of language milestones as predictors of developmental trajectories in young children with autism spectrum disorder. J. Autism Dev. Disord. 2016 46 7 2501 2507 10.1007/s10803‑016‑2756‑y 26936159
    [Google Scholar]
  61. Weitzman C. Wegner L. Promoting optimal development: screening for behavioral and emotional problems. Pediatrics 2015 135 2 384 395 10.1542/peds.2014‑3716 25624375
    [Google Scholar]
  62. Lipkin P.H. Macias M.M. Norwood K.W. Jr Brei T.J. Davidson L.F. Davis B.E. Ellerbeck K.A. Houtrow A.J. Hyman S.L. Kuo D.Z. Noritz G.H. Yin L. Murphy N.A. Levy S.E. Weitzman C.C. Bauer N.S. Childers D.O. Jr Levine J.M. Peralta-Carcelen A.M. Smith P.J. Blum N.L. Contompasis S.H. Korb D.R. McGuinn L.J. Voigt R.G. Promoting optimal development: Identifying infants and young children with developmental disorders through developmental surveillance and screening. Pediatrics 2020 145 1 e20193449 10.1542/peds.2019‑3449 31843861
    [Google Scholar]
  63. Portaccio E. Annovazzi P. Ghezzi A. Zaffaroni M. Moiola L. Martinelli V. Lanzillo R. Brescia Morra V. Rinaldi F. Gallo P. Tortorella C. Paolicelli D. Pozzilli C. De Giglio L. Cavalla P. Cocco E. Marrosu M.G. Patti F. Solaro C. Bellantonio P. Uccelli A. Laroni A. Pastò L. Giannini M. Trojano M. Comi G. Amato M.P. Amato M.P. Portaccio E. Hakiki B. Pastò L. Giannini M. Razzolini L. Righini I. Siracusa G. Ghezzi A. Annovazzi P. Zaffaroni M. Martinelli V. Radaelli M. Moiola L. Comi G. Protti A. Susani E. Marazzi R. Confalonieri P. Torri Clerici V. Cavalla P. Chiavazza C. Bergamaschi R. Mancardi G. Uccelli A. Capello E. Laroni A. Solaro C. Tola M.R. Caniatti L. Granella F. Annunziata P. Plewnia K. Guidi L. Bartolozzi M.L. Mazzoni M. Pozzilli C. De Giglio L. Totaro R. Carolei A. Rossi M. Lugaresi A. De Luca G. Di Tommaso V. Tortorella C. Paolicelli D. D’Onghia M. Trojano M. Marrosu M.G. Cocco E. Melis M. Patti F. Leone C. Lo Fermo S. Bellantonio P. Fantozzi R. Gasperini C. Iudice A. Bosco A. Sartori A. Lanzillo R. Brescia Morra V. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology 2018 90 10 90 e31 [published correction appears in Neurology, 94, 504]. 10.1212/WNL.0000000000005067
    [Google Scholar]
  64. Sotgiu S. Eusebi A. Begliuomini C. Guerini F.R. Carta A. Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018 91 18 850 10.1212/WNL.0000000000006429 30373925
    [Google Scholar]
  65. Portaccio E. Pastò L. Razzolini L. Moiola L. Martinelli V. Annovazzi P. Ghezzi A. Zaffaroni M. Lanzillo R. Brescia Morra V. Rinaldi F. Gallo P. Gasperini C. Paolicelli D. Simone M. Pozzilli C. De Giglio L. Cavalla P. Cocco E. Marrosu M.G. Patti F. Solaro C. Comi G. Filippi M. Trojano M. Amato M.P. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Mult. Scler. 2022 28 13 2137 2141 10.1177/13524585221079598 35296189
    [Google Scholar]
  66. Thiel S. Langer-Gould A. Rockhoff M. Haghikia A. Queisser-Wahrendorf A. Gold R. Hellwig K. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult. Scler. 2016 22 6 801 809 10.1177/1352458516634872 26920382
    [Google Scholar]
  67. Hakkarainen K.M. Juuti R. Burkill S. Geissbühler Y. Sabidó M. Popescu C. Suzart-Woischnik K. Hillert J. Artama M. Verkkoniemi-Ahola A. Myhr K.M. Mehtälä J. Bahmanyar S. Montgomery S. Korhonen P. Adamo A. Wicklein E-M. Akbaba M. Borghesi G. Köfüncü E. Everage N. Pandhi A. Naylor M. Ly A. Jack D. Todorovic M. Issard D. Macklin A. Primatesta P. Weitzman R. Klement R. Vehkala M. Vattulainen P. Korjagina M. Gyllensten H. Pregnancy outcomes after exposure to interferon beta: A register-based cohort study among women with MS in Finland and Sweden. Ther. Adv. Neurol. Disord. 2020 13 1756286420951072 10.1177/1756286420951072 33101459
    [Google Scholar]
  68. Hellwig K. Duarte Caron F. Wicklein E.M. Bhatti A. Adamo A. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther. Adv. Neurol. Disord. 2020 13 1756286420910310 10.1177/1756286420910310 32201504
    [Google Scholar]
  69. Thöne J. Thiel S. Gold R. Hellwig K. Treatment of multiple sclerosis during pregnancy – safety considerations. Expert Opin. Drug Saf. 2017 16 5 523 534 10.1080/14740338.2017.1311321 28333552
    [Google Scholar]
  70. Hellwig K. Haghikia A. Rockhoff M. Gold R. Multiple sclerosis and pregnancy: Experience from a nationwide database in Germany. Ther. Adv. Neurol. Disord. 2012 5 5 247 253 10.1177/1756285612453192 22973421
    [Google Scholar]
  71. Carbone L. Landi D. Di Girolamo R. Anserini P. Centonze D. Marfia G.A. Alviggi C. Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey. Front. Neurol. 2023 14 1255496 10.3389/fneur.2023.1255496 37869135
    [Google Scholar]
  72. Airas L. Exposure to natalizumab during pregnancy and lactation is safe – No. Mult. Scler. 2020 26 8 889 891 10.1177/1352458520917934 32508200
    [Google Scholar]
  73. Hellwig K. Tokic M. Thiel S. Hemat S. Timmesfeld N. Ciplea A.I. Gold R. Langer-Gould A.M. Multiple sclerosis disease activity and disability following cessation of fingolimod for pregnancy. Neurol. Neuroimmunol. Neuroinflamm. 2023 10 4 e200110 10.1212/NXI.0000000000200110 37217309
    [Google Scholar]
  74. Mastenbroek L.J.M. Kooistra S.M. Eggen B.J.L. Prins J.R. The role of microglia in early neurodevelopment and the effects of maternal immune activation. Semin. Immunopathol. 2024 46 1-2 1 10.1007/s00281‑024‑01017‑6 38990389
    [Google Scholar]
  75. Osman H.C. Moreno R. Rose D. Rowland M.E. Ciernia A.V. Ashwood P. Impact of maternal immune activation and sex on placental and fetal brain cytokine and gene expression profiles in a preclinical model of neurodevelopmental disorders. J. Neuroinflammation 2024 21 1 118 10.1186/s12974‑024‑03106‑7 38715090
    [Google Scholar]
  76. Patas K. Engler J.B. Friese M.A. Gold S.M. Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity. J. Reprod. Immunol. 2013 97 1 140 146 10.1016/j.jri.2012.10.005 23432880
    [Google Scholar]
/content/journals/cn/10.2174/011570159X370866250416103923
Loading
Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study
Bentham Science Publishers ; https://doi.org/10.2174/011570159X370866250416103923
/content/journals/cn/10.2174/011570159X370866250416103923
/content/journals/cn/10.2174/011570159X370866250416103923
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: autism ; pregnancy ; children ; Multiple sclerosis ; neurodevelopment ; natalizumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test